NCT00250276View on ClinicalTrials.gov

Evaluation of the Immune Responses of GSK Biologicals' HPV Vaccine Following Manufacturing Process Adaptation.

PHASE3CompletedINTERVENTIONAL
Enrollment

798

Participants

Timeline

Start Date

October 28, 2005

Primary Completion Date

March 1, 2007

Study Completion Date

March 1, 2007

Conditions
Infections, PapillomavirusPapillomavirus Vaccines
Interventions
BIOLOGICAL

Cervarix™

GSK Biologicals' vaccine against human papillomaviruses 16 and 18.

Trial Locations (8)

DK-2650

GSK Investigational Site, Hvidovre

LT-50009

GSK Investigational Site, Kaunas

LT-93200

GSK Investigational Site, Klaipėda

LT-07156

GSK Investigational Site, Vilnius

LT-10207

GSK Investigational Site, Vilnius

31-501

GSK Investigational Site, Krakow

60-533

GSK Investigational Site, Poznan

01-211

GSK Investigational Site, Warsaw

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY